Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.615
-0.025 (-1.52%)
Mar 31, 2025, 2:26 PM EDT - Market open
Immuneering Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Immuneering stock have an average target of 11, with a low estimate of 8.00 and a high estimate of 13. The average target predicts an increase of 581.11% from the current stock price of 1.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 7 | 7 | 7 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +704.95% | Mar 24, 2025 |
Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +643.03% | Mar 21, 2025 |
Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +643.03% | Feb 6, 2025 |
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +828.79% | Jan 13, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +704.95% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.91
from -2.04
EPS Next Year
-2.20
from -1.91
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 86.6M | ||
Avg | n/a | n/a | 42.1M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.72 | -1.97 | -1.05 | ||
Avg | -1.91 | -2.20 | -1.91 | ||
Low | -2.25 | -2.52 | -2.70 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.